Invokana (Canagliflozin) is a gliflozin class drug also known as a subtype 2 sodium-glucose transport inhibitor (SGLT-2) that is used for treatment of diabetes mellitus type 2.  Invokana is meant to assist in lowering blood sugar levels for Type 2 Diabetics. Invokana is manufactured and sold by Janssen Pharmaceuticals, Inc. and its associated/affiliated companies.

Invokana, it has been discovered, can cause diabetic ketoacidosis/ketosis, kidney failure, and/or cardiovascular events, including myocardial infarctions.  DKA (diabetic ketoacidosis), a subset of ketoacidosis or ketosis in diabetic patients, is a type of acidosis that typically occurs when insulin levels are inadequate to meet the body’s basic metabolic requirements. Physical symptoms include nausea, vomiting, and abdominal pain that can progress to cerebral edema, coma, and death.

The Levensten Law Firm is involved in the Invokana litigation. Please contact our firm for a free consultation regarding your possible Invokana litigation claim.